| Autor: |
Syed, Abidi, Jay, Achar, Mourtala Mohamed, Assao Neino, Didi, Bang, Andrea, Benedetti, Sarah, Brode, Jonathon R, Campbell, Esther C, Casas, Francesca, Conradie, Gunta, Dravniece, Philipp, du Cros, Dennis, Falzon, Ernesto, Jaramillo, Christopher, Kuaban, Zhiyi, Lan, Christoph, Lange, Pei Zhi, Li, Mavluda, Makhmudova, Aung Kya Jai, Maug, Dick, Menzies, Giovanni Battista, Migliori, Ann, Miller, Bakyt, Myrzaliev, Norbert, Ndjeka, Jürgen, Noeske, Nargiza, Parpieva, Alberto, Piubello, Valérie, Schwoebel, Welile, Sikhondze, Rupak, Singla, Mahamadou Bassirou, Souleymane, Arnaud, Trébucq, Armand, Van Deun, Kerri, Viney, Karin, Weyer, Betty Jingxuan, Zhang, Faiz, Ahmad Khan |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
The European respiratory journal. 55(3) |
| ISSN: |
1399-3003 |
| Popis: |
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a standardised regimen of 9-12 months (the "shorter regimen") and individualised regimens of ≥20 months ("longer regimens").We collected individual patient data from observational studies identified through systematic reviews and a public call for data. We included patients meeting WHO eligibility criteria for the shorter regimen: not previously treated with second-line drugs, and with fluoroquinolone- and second-line injectable agent-susceptible RR/MDR-TB. We used propensity score matched, mixed effects meta-regression to calculate adjusted odds ratios and adjusted risk differences (aRDs) for failure or relapse, death within 12 months of treatment initiation and loss to follow-up.We included 2625 out of 3378 (77.7%) individuals from nine studies of shorter regimens and 2717 out of 13 104 (20.7%) individuals from 53 studies of longer regimens. Treatment success was higher with the shorter regimen than with longer regimens (pooled proportions 80.0% |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
